Operational Costs Compared: SG&A Analysis of Amgen Inc. and Cytokinetics, Incorporated

A Decade of SG&A: Amgen vs. Cytokinetics

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Amgen Inc. and Cytokinetics, Incorporated have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Amgen, a biotech giant, consistently reported SG&A expenses averaging around $5.3 billion annually, peaking at $6.2 billion in 2023. This reflects a steady growth of approximately 31% from 2014. In contrast, Cytokinetics, a smaller player, saw its SG&A expenses rise dramatically by over 900%, from $17 million in 2014 to $174 million in 2023. This stark difference highlights the scale and operational strategies of these companies. While Amgen's expenses reflect its expansive global operations, Cytokinetics' growth underscores its aggressive push in the biotech sector. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.